{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:18:41Z","timestamp":1772749121781,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1016\/j.amjmed.2003.09.004","type":"journal-article","created":{"date-parts":[[2003,12,11]],"date-time":"2003-12-11T07:47:40Z","timestamp":1071128860000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"S1","title":["Free fatty acids and type 2 diabetes mellitus"],"prefix":"10.1016","volume":"115","author":[{"given":"Kathleen L","family":"Wyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2003.09.004_BIB1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB2","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2337\/diabetes.50.7.1612","article-title":"Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects","volume":"50","author":"Boden","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/1522-2594(200102)45:2<179::AID-MRM1023>3.0.CO;2-D","article-title":"Fast elevation of the intramyocellular lipid content in the presence of circulating free fatty acids and hyperinsulinemia","volume":"45","author":"Brechtel","year":"2001","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2337\/diabetes.51.1.7","article-title":"Banting lecture 2001","volume":"51","author":"McGarry","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2337\/diabetes.52.1.138","article-title":"Intramyocellular lipid and insulin resistance","volume":"52","author":"Kuhlmann","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2337\/diab.46.6.1001","article-title":"Metabolic defects in lean nondiabetic offspring of NIDDM parents","volume":"46","author":"Perseghin","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2337\/diacare.24.2.328","article-title":"Plasma levels of tumor necrosis factor-\u03b1, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance","volume":"24","author":"Bl\u00fcher","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/hc3201.094151","article-title":"Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population","volume":"104","author":"Jouven","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB9","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/01.ATV.20.6.1588","article-title":"High levels of nonesterified fatty acids are associated with increased familial risk of cardiovascular disease","volume":"20","author":"Carlsson","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI119546","article-title":"The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation","volume":"100","author":"Stein","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB11","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2337\/diabetes.50.8.1771","article-title":"Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation","volume":"50","author":"Cnop","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2337\/diabetes.51.5.1437","article-title":"Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets","volume":"51","author":"Lupi","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB13","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1073\/pnas.0630588100","article-title":"Triglyceride accumulation protects against fatty acid\u2013induced lipotoxicity","volume":"18","author":"Listenberger","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.physiol.65.092101.142622","article-title":"The physiology of cellular liporegulation","volume":"65","author":"Unger","year":"2003","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI5001","article-title":"Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity","volume":"103","author":"Dresner","year":"1999","journal-title":"J Clin Invest"},{"issue":"suppl 5A","key":"10.1016\/j.amjmed.2003.09.004_BIB16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0002-9343(88)90402-0","article-title":"Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus","volume":"85","author":"Reaven","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1172\/JCI118160","article-title":"Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes","volume":"96","author":"Boden","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1525-1381.1999.99220.x","article-title":"Free fatty acids, insulin resistance, and type 2 diabetes mellitus","volume":"3","author":"Boden","year":"1999","journal-title":"Proc Assoc Am Phys"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1126\/science.1439783","article-title":"What if Minkowski had been ageusic?. An alternative angle on diabetes","volume":"258","author":"McGarry","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.med.53.082901.104057","article-title":"Lipotoxic diseases","volume":"53","author":"Unger","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1096\/fj.00-0590","article-title":"Diseases of liporegulation","volume":"15","author":"Unger","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB22","first-page":"E708","article-title":"Tissue triglycerides, insulin resistance, and insulin production","volume":"273","author":"Koyama","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB23","doi-asserted-by":"crossref","first-page":"32487","DOI":"10.1074\/jbc.273.49.32487","article-title":"Lipoapoptosis in beta-cells of obese prediabetic fa\/fa rats","volume":"273","author":"Shimabukuro","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB24","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1073\/pnas.91.23.10878","article-title":"\u03b2-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats","volume":"91","author":"Lee","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB25","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes","volume":"44","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB26","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1074\/jbc.273.6.3547","article-title":"Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats","volume":"273","author":"Shimabukuro","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2337\/diabetes.50.5.1021","article-title":"\u03b2-Cell mass dynamics in Zucker diabetic fatty rats","volume":"50","author":"Finegood","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB28","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/oby.2002.137","article-title":"Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]","volume":"10","author":"Carey","year":"2002","journal-title":"Obes Res"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB29","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s001250100031","article-title":"Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients","volume":"44","author":"Miyazaki","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB30","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.2337\/diabetes.50.5.1158","article-title":"Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability","volume":"50","author":"Oakes","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB32","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","article-title":"Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients","volume":"87","author":"Miyazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB33","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1172\/JCI118709","article-title":"Obesity\/insulin resistance is associated with endothelial dysfunction","volume":"97","author":"Steinberg","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB34","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.RES.87.10.840","article-title":"Endothelial dysfunction in cardiovascular diseases","volume":"87","author":"Cai","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB35","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2337\/diab.41.9.1076","article-title":"Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM","volume":"41","author":"Laakso","year":"1992","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1172\/JCI11235","article-title":"Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site","volume":"108","author":"Du","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB37","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/hc0502.103333","article-title":"Insulin causes endothelial dysfunction in humans","volume":"105","author":"Arcaro","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB38","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.HYP.25.4.774","article-title":"Fatty acids enhance vascular \u03b1-adrenergic sensitivity","volume":"25","author":"Stepniakowski","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB39","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1210\/jcem.81.12.8954022","article-title":"Does free fatty acid infusion impair insulin action also through an increase in oxidative stress?","volume":"81","author":"Paolisso","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB40","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1210\/jcem.87.6.8596","article-title":"FFA-induced endothelial dysfunction can be corrected by vitamin C","volume":"87","author":"Pleiner","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB41","first-page":"E686","article-title":"Effect of free fatty acids on blood amino acid levels in humans","volume":"250","author":"Ferrannini","year":"1986","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB42","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.HYP.26.5.764","article-title":"Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism","volume":"26","author":"Davda","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB43","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2165\/00003495-200262100-00004","article-title":"Metabolic and additional vascular effects of thiazolidinediones","volume":"62","author":"Martens","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199901073400103","article-title":"Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults","volume":"340","author":"O'Leary","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB45","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.101.11.1311","article-title":"Expression and function of PPAR\u03b3 in rat and human vascular smooth muscle cells","volume":"101","author":"Law","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB46","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1210\/jcem.83.5.4932","article-title":"Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes","volume":"83","author":"Minamikawa","year":"1998","journal-title":"J Clin Endrocrinol Metab"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB47","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1210\/jcem.86.7.7810","article-title":"Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes","volume":"86","author":"Koshiyama","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(00)00895-0","article-title":"Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin-dependent diabetes mellitus","volume":"36","author":"Takagi","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB49","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0895-7061(95)96214-5","article-title":"Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives","volume":"8","author":"Ogihara","year":"1995","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/01.HYP.34.1.83","article-title":"Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus","volume":"34","author":"Sung","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB51","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1210\/jc.2002-020963","article-title":"Effects of pioglitazone in nondiabetic patients with arterial hypertension","volume":"87","author":"Fullert","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.jhh.1001444","article-title":"Rosiglitazone reduces urinary albumin excretion in type II diabetes","volume":"17","author":"Bakris","year":"2003","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB53","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/diacare.26.1.172","article-title":"Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients","volume":"26","author":"Raji","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB54","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1172\/JCI118041","article-title":"Blood pressure lowering by pioglitazone","volume":"96","author":"Buchanan","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB55","doi-asserted-by":"crossref","first-page":"18919","DOI":"10.1074\/jbc.M110650200","article-title":"Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus","volume":"277","author":"Sun","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB56","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1053\/euhj.2000.2248","article-title":"Microalbuminuria is independently associated with ischaemic electrographic abnormalities in a large non-diabetic population","volume":"21","author":"Diercks","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1524-6175.2001.00442.x","article-title":"Microalbuminuria","volume":"3","author":"Bakris","year":"2001","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1191\/1358863x02vm412ra","article-title":"Microalbuminuria","volume":"7","author":"Garg","year":"2002","journal-title":"Vasc Med"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB59","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis, and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB60","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1056-8727(00)00124-0","article-title":"Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients","volume":"14","author":"Nakamura","year":"2000","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB61","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/meta.2001.26703","article-title":"Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria","volume":"50","author":"Nakamura","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB62","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/diacare.22.2.355","article-title":"Troglitazone directly increases HDL cholesterol levels","volume":"22","author":"Nozue","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB63","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2337\/diacare.21.5.796","article-title":"Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects","volume":"21","author":"Tack","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB64","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0002-9149(02)02659-0","article-title":"Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus","volume":"90","author":"Freed","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB65","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0149-2918(02)85040-8","article-title":"Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus","volume":"24","author":"Boyle","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB66","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1185\/03007990152673819","article-title":"Pioglitazone","volume":"17","author":"Baba","year":"2001","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00019501-200108000-00011","article-title":"The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus","volume":"12","author":"Rosenblatt","year":"2001","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/meta.2002.30506","article-title":"Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes","volume":"51","author":"Hirose","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB69","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0149-2918(00)83039-8","article-title":"Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus","volume":"22","author":"Einhorn","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9343(01)00713-6","article-title":"Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus","volume":"111","author":"Kipnes","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB71","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/ajhp\/60.5.469","article-title":"Effects of pioglitazone on diabetes-related outcomes in Hispanic patients","volume":"60","author":"Jun","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB72","doi-asserted-by":"crossref","unstructured":"Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875\u2013881","DOI":"10.1001\/jama.1996.03540110029028"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB73","doi-asserted-by":"crossref","unstructured":"Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882\u2013888","DOI":"10.1001\/jama.1996.03540110036029"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB74","doi-asserted-by":"crossref","unstructured":"Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Qu\u00e9bec Cardiovascular Study. Circulation. 1997;95:69\u201375","DOI":"10.1161\/01.CIR.95.1.69"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB75","doi-asserted-by":"crossref","unstructured":"Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 2002;160:41\u201348","DOI":"10.1016\/S0021-9150(01)00544-5"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB76","doi-asserted-by":"crossref","unstructured":"The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360\u2013381","DOI":"10.1001\/jama.1975.03240160024021"},{"key":"10.1016\/j.amjmed.2003.09.004_BIB77","doi-asserted-by":"crossref","unstructured":"Marals AD. Therapeutic modulation of low-density lipoprotein size. Curr Opin Lipidol. 2000;11:597\u2013602","DOI":"10.1097\/00041433-200012000-00005"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293430300562X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293430300562X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:28:58Z","timestamp":1757579338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293430300562X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S000293430300562X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2003.09.004","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Free fatty acids and type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2003.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Excerpta Medica Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}